Rituximab

DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.

Rituximab was associated with significant improvements in both skin and lung parameters over long-term follow-up in a cohort of patients with systemic sclerosis, according to a study.

Research has shown that breakthrough SARS-CoV-2 infections are common among patients using rituximab. However, a new study found that few rituximab users who are fully vaccinated against COVID-19 develop severe symptoms.

Although the breakthrough infection rate has been high in patients using rituximab during the later stages of the COVID-19 pandemic, a small proportion of those who are fully vaccinated develop severe outcomes, according to data.

NEW ORLEANS — Health-related quality of life in patients with diffuse large B-cell lymphoma improved in a comparison of two therapy regimens.

NEW ORLEANS — Cost efficacy of polatuzumab vedotin added to traditional treatments for diffuse large B-cell lymphoma in the front-line requires long-term PFS data, according to a poster presented at ASH Annual Meeting and Exhibition.

In patients with granulomatosis with polyangiitis, those who start induction therapy with rituximab are more likely to achieve remission compared with those who begin cyclophosphamide, according to data published in JAMA Network Open.

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.